可溶性E-选择素与慢性乙型肝炎的关系

近年来 ,血清可溶性E 选择素 (sE selectin)变化与各种肝病之间的关系越来越受到人们的重视。Adams等[1 ,2 ] 曾报道酒精性肝病、原发性胆汁性肝硬化患者外周血sE selectin明显增高。我们检测了 54例慢性乙型肝炎患者外周血sE selectin水平 ,并分析其与肝功能、肝纤维化指标及血清HBVDNA定量的关系 ,以探讨其临床意义。材料和方法一、研究对象54例慢性乙型病毒性肝炎 (简称慢乙肝 )患者 ,男 3 5例 ,女 19例 ,平均年龄 ( 3 9.2 3± 18.92 )岁。根据 2 0 0 0年 9月西安会议制订的病毒性肝炎防治方案的诊断标准[3 ] ,其中轻度 19例 ,中度 …     

慢性乙型肝炎患者血浆可溶性E和P选择素的检测及临床意义

选择素是细胞黏附分子的一种,近年来发现与许多疾病密切相关,尤其与慢性肝病之间的关系已越来越受到人们的重视.我们检测了60例慢性乙型肝炎（慢性乙肝）患者外周血可溶性E选择素（sE-selectin）和可溶性P选择素（sP-selectin）的含量,并分析其与肝功能指标的相关性,以探讨其临床意义.     

慢性乙型肝炎和肝硬化患者血清HA、LN、PCⅢ和Ⅳ-C水平与肝组织纤维化程度的关系

目的 探讨慢性乙型肝炎和肝硬化患者血清透明质酸（HA）、层粘连蛋白（LN）、Ⅲ型前胶原（PCⅢ）和Ⅳ型胶原（Ⅳ－C）在肝纤维化诊断中的应用价值。方法 采用放射免疫法检测150例慢性乙型肝炎和肝硬化患者血清HA、LN、PVⅢ和Ⅳ－C水平，并与活检肝组织纤维化程度进行相关性分析。结果 各组慢性乙型肝炎患者血清HA、LN、PCⅢ和Ⅳ－C水平均高于正常对照组，与肝纤维化活动水平及程度呈密切正相关。结论 血清HA、LN、PCⅢ和Ⅳ－C水平能较好地反映乙型肝炎纤维化程度，联合检测可明显提高肝纤维化诊断的准确性和可靠性。     

慢性乙型肝炎患者血清Ⅲ型前胶原、Ⅲ型胶原的前胶原氨端肽原的比较研究

比较慢性肝炎患者血清Ⅲ型前胶原（PCⅢ）与Ⅲ型胶原的前胶原氨端肽原（PⅢNP)对诊断肝纤维化的实用价值。对114例肝穿病理诊断的慢性肝炎轻、中、重度患者，同时进行血清PCⅢ及PⅢNP的检测，均用放射免疫法。肝穿刺标本病理组织学检查，作肝炎症活动度分级、肝纤维化程度分期及慢性肝炎病理组织学分度，探讨PCⅢ及PⅢNP与它们关系。114例轻、中、重度慢性肝炎患者，PCⅢ及PⅢNP之间均有显著差异（P＜0．01）。这2项指标均与肝脏炎活动度分级、肝纤维化程度分期及慢性肝炎的病理组织学分度有关。相关系数PCⅢ0．446、0．412和0．343；PⅢNP为0．463、0．403和0．308。PCⅢ及PⅢNP检测对慢性肝炎肝纤维化的诊断均有意义，PⅢNPO在早期肝纤维化方面比PCⅢ敏感。     

慢性肝病肝血瘀阻与血清肝纤维化标志物关系的探讨

目的：探讨慢性肝病肝血瘀阻与血清肝纤维化标志物之间的关系，认识肝纤维化的中医病因病机本质，方法：采用放射免疫法测定１５２例慢性肝病血瘀证与非血瘀证患者及３５例对照组的血清透明质酸，Ⅲ型前胶原，Ⅳ型胶原。结果；血瘀证和非血瘀证血清ＨＡ，ｈＰＣⅢ，Ⅳ－Ｃ３项均显著高于对照组，其中血瘀证组血清的ＨＡ，ｈＰＣⅢ两项显著高于非血瘀证组。     

慢性乙型肝炎肝纤维化分期与血清肝纤维化标志物的相关性分析

目的 探讨血清透明质酸、Ⅲ型前胶原、层粘蛋白、Ⅳ型胶原等血清肝纤维化标志物与慢性肝炎肝组织炎症活动度及纤维化程度的相关性。方法 278例慢性肝炎患者经肝脏活栓后常规病理检查,肝活检前同时采血检测血清透明质酸、Ⅲ型前胶原、层粘蛋白、Ⅳ型胶原,结果应用x^2检验及t检验进行统计学处理。结果 肝组织纤维化程度与炎症活动度呈正相关关系,透明质酸可反映中度以上慢性肝炎炎症活动度及纤维化程度,且呈正相关;肝脏存在纤维化时层粘蛋白水平升高,与纤维化程度正相关;Ⅲ型前胶原、Ⅳ型胶原水平升高与炎症活动度有关。结论 血清透明质酸、Ⅲ型前胶原、层粘蛋白、Ⅳ型胶原可不同程度反映肝纤维纤维化程度,可作为血清肝纤维化检测指标,透明质酸更可反映肝硬化发展趋势。     

血清肝纤维化指标水平与肝组织纤维图象分析的关系

目的 探讨血清肝纤维化指标透明质酸（ＨＡ）,Ⅲ型前胶原（ＰＣⅢ）、Ⅲ型胶原（ＣⅣ）水平与肝组织纤维化程度的关系及对慢性病毒性肝炎肝纤维化的临床意义,方法 用放射免疫法测定１５１例慢性病毒性肝炎患者血清ＨＡ、ＰＣⅢ、ＣⅣ水平,所有患者均做肝活组织检查,对肝组织标本行Ｍａｓｓｏｎ法网状纤维染色,在计算机图象分析系统下对肝组织网状纤维染色标本进行纤维组织定量测定。结果 血清ＨＡ、ＰＣⅢ、ＣⅣ水平与肝组织     

92例慢性乙型肝炎患者血清纤维化指标观察

2004年2月～2005年2月，我们对92例慢性乙型肝炎（慢乙肝）患者的肝纤维化指标透明质酸（HA）、层黏蛋白（LN）、Ⅳ型胶原（Ⅳ-C）、血清Ⅲ型前胶原（PCⅢ）进行了检测，以探讨其血清浓度与病情及预后的意义。     

慢性乙型肝炎患者外周血淋巴细胞凋亡与血清HBVDNA定量关系的研究

探讨慢性乙型肝炎患者外周血淋巴细胞凋亡与血清HBV DNA定量的关系。分别采用流式细胞计数仪和荧光定量PCR法检测慢性乙型肝炎患者外周血淋巴细胞凋亡率与血清HBV DNA。慢性乙型肝炎患者外周血淋巴细胞凋亡率明显高于正常对照组，且与血清HBV DNA水平呈正相关。慢性乙型肝炎患者外周血淋巴细胞凋亡水平异常可能与HBV的持续感染与复制相关联。     

α干扰素治疗慢性乙型肝炎前后血清PC Ⅲ和HA水平的变化

用α干扰素治疗慢性乙型肝炎31例,检测了治疗前后血清Ⅲ型前胶原(PCⅢ)和透明质酸(HA)的含量变化。结果,治疗组疗程结束后血清PCⅢ和HA含量显著降低,而对照组无显著性变化;血清HBV DNA阴转者血清PCⅢ和HA水平明显低于未阴转者,表明α干扰素可减轻慢性乙型肝炎患者肝纤维化的程度及活动性,其抗肝纤维化作用与抗病毒作用密切相关。     

慢性乙型肝炎肝脏病理与可溶性白细胞介素2受体关系探讨

目的探讨慢性乙型肝炎病理与血清中可溶性白细胞介素2受体(sIL-2R)在慢性乙型肝炎发病机制中的作用和临床应用的价值.方法采用双抗体夹心酶联免疫法检测了307例病人血清sIL-2R(其中275例慢性乙型肝炎和16例脂肪肝均做了肝活检,16例慢性重型肝炎未做肝活检),用自动生化分析仪检测了血清总胆红素(TB)、白蛋白(A)、球蛋白(G)、丙氨酸转氨酶(ALT)、碱性磷酸酶(ALP)和γ-谷氨酰转肽酶(γ-GT)等指标在肝脏病理各级炎症及各期纤维化中的改变.结果血清sIL-2R、TB、G、ALT、ALP和γ-GT均值随着肝脏病理炎症程度加重而逐渐增高,A均值则随着肝脏病理炎症程度加重逐渐下降,各组间比较有显著性差异P＜0.05或P＜0.01.sIL-2R、G均值随着肝纤维化的进展而逐渐增高,A均值则随着肝纤维化的进展而逐渐下降,各组间比较有显著性差异P＜0.05或P＜0.01.结论慢性乙型肝炎病人血清sIL-2R、TB、A、G、ALT、ALP和γ-GT水平的变化可作为判定肝组织炎症程度的参考指标,sIL-2R、A、G可作为判定肝纤维化程度的参考指标.     

慢性乙型肝炎患者肝组织Fas表达与血清可溶性Fas水平的关系

目的探讨患者肝组织中Fas的表达与血清可溶性Fas水平的关系。方法用免疫组化方法检测60例慢性乙型肝炎患者肝组织Fas的表达,同时用酶联免疫吸附试验检测血清可溶性Fas。结果重度慢性乙型肝炎患者血清中sFas水平>中度>轻度,各组间差异有显著意义(P<0.01);慢性乙型肝炎患者肝组织Fas表达的程度和血清sFas水平与肝组织病变的活动性一致。结论 1.肝组织炎症程度与肝组织Fas抗原的表达有关;2.Fas介导的肝细胞凋亡在慢性乙型肝炎的发病机制中起重要作用,抑制肝细胞Fas表达有助于减轻肝细胞损伤程度。     

Role of serum soluble Fas/soluble Fas ligand and TNF-alpha on response to interferon-alpha therapy in chronic hepatitis C

AIMS/BACKGROUND: To determine the relationship between host factors and host response to interferon (IFN) therapy, serum soluble Fas (sFas), soluble Fas ligand (sFas ligand), and tumor necrosis factor-alpha (TNF-alpha) were analyzed in 41 patients with chronic hepatitis C (CH-C) treated with IFN-alpha. METHODS: Serum levels of sFas, sFas ligand, and TNF-alpha were measured at 0, 4, and 24 weeks of IFN therapy. RESULTS: Eighteen patients were complete responders (CR) and 23 patients were non-responders (NR). Serum levels of sFas and TNF-alpha in patients with CHC were significantly higher than those in healthy controls (p<0.01 and p<0.01, respectively). Serum sFas ligand levels were significantly lower in CH-C patients than in healthy controls (p<0.01). Before IFN therapy, serum levels of sFas in NR were significantly higher than those in CR (p<0.05). At 4 weeks of IFN therapy, serum levels of sFas of CR were significantly elevated compared with levels before IFN therapy (p<0.05). Serum levels of sFas correlated with the histological activity of the liver (p<0.05) and alanine aminotransferase (p<0.05). None of the three parameters, serum sFas, sFas ligand, or TNF-alpha levels, correlated with each other, with HCV-RNA genotype or with serum HCV-RNA load. Multiple logistic regression analysis showed that serum sFas levels before IFN therapy were a contributive factor to predict efficacy of IFN therapy. CONCLUSIONS: Serum sFas/sFas ligand and TNF-alpha play a possible role in pathogenesis of CH-C and also in IFN therapy. Serum sFas levels before IFN therapy may be one of the host-related factors used for evaluating the response of CH-C patients to IFN therapy.     

慢性乙型肝炎血清HBVDNA临床诊断与病理分度的关系

为探讨慢性乙型肝炎时血清ＨＢＶＤＮＡ与病理分度，临床诊断便分度的关系，对１４０例慢性乙型肝炎患者进行ＨＢＶＤＮＡ检测，肝活检，行临床诊断与病理分度对照，ＨＢＶＤＮＡ阴，阳组间比较。结果显示临床诊断与病理分度符合率，慢轻肝７５．８％，慢中肝４３．２８％，慢重肝不符合，ＨＢＶＤＮＡ阳性组病例程度明显加重，差异显著。随炎症活动度增加，ＡＬＴ值升高愈明显，结论提示慢性中重度患者应行病理检查，ＡＬＴ仍然观察     

Relation between treatment efficacy and cumulative dose of alpha interferon in chronic hepatitis B

Background/Aims: Alpha interferon (IFN) is an established treatment of chronic hepatitis B. The effect has been shown to be dose related, recommended dose regimens being associated with a doubling of the spontaneous, baseline HBeAg to anti-HBe seroconversion rate. However, the efficacy of IFN treatment in relation to the dose of IFN actually received remains to be established. The aim of this study was to estimate the relative efficacy of IFN as a function of the cumulative IFN dose. In addition we determined if and when a patient returns to his baseline chance of seroconversion after stopping IFN therapy.Materials and Methods: Individual patient data from 10 clinical controlled trials were available for the present analysis, in all, 746 patients, of whom 491 received IFN and 255 were untreated controls. The data were analyzed performing a time-dependent Cox regression analysis of the relative efficacy of IFN using the cumulative IFN dose administered up to any given time during the observation period and the time after termination of therapy as explanatory variables.Results: In the proposed model, the chance of HBeAg disappearance for a treated patient relative to no therapy was estimated to 2.1 at a cumulative dose of 100 MU and leveled out at about 2.8 at a cumulative dose of 500 MU. The effect of IFN was shown to decay repidly after discontinuation and after 3 months a patient could be considered to be back to his baseline chance of HBeAg disappearance. These findings show that IFN administered at a dose of 15–30 MU/week should be considered effective (relative efficacy≈2) already after 1–2 months of treatment.Conclusions: The present findings do not lend any support to the concept that IFN treatment becomes less effective when a certain total dose of IFN has been administered or that the treatment effect reaches beyond 3 months after stopping IFN.     

Association between angiogenesis soluble factors and disease progression markers in chronic hepatitis C patients.

OBJECTIVES: Our objectives were to compare angiogenesis soluble factor (ASF) levels in chronic hepatitis C (CHC) patients and healthy individuals, and to investigate potential associations between ASF levels and both histological and biochemical markers of disease progression. METHOD: Thirty-six patients (69% males) positive for HCV-RNA by PCR analysis were included in the study. All patients underwent liver biopsy before treatment. Serum levels of vascular endothelial growth factor (VEGF), soluble Flt-1 and Flk-1 receptors, placental growth factor (PlGF), angiopoietin-2 (Ang-2) and soluble Tie-2 receptor were determined by ELISA. Fifteen healthy subjects were used as controls. RESULTS: In comparison to healthy individuals, CHC patients showed significantly increased serum levels of proangiogenic factors PlGF (22 +/- 5 vs. 18 +/- 8 pg/ml; p < 0.05), Ang-2 (1265 +/- 385 vs. 833 +/- 346 pg/ml; p < 0.005) and sFlt-1 (95 +/- 22 vs. 72 +/- 14 pg/ml; p < 0.0001). Interestingly, in CHC patients serum levels of VEGF and Tie-2 correlated with grade of inflammation, PlGF correlated with stage of fibrosis, and Flt-1 and Flk-1 correlated with serum transaminase levels (p < 0.05 in all cases). CONCLUSIONS: CHC patients showed increased serum levels of ASF, and a significant correlation was shown between serum levels of selected ASFs and grade of inflammation, stage of fibrosis, and transaminase levels.